0 CHECKOUT

Schistosomiasis - Pipeline Review, H1 2015

  • ID: 3231032
  • April 2015
  • 36 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • BioDiem Ltd
  • Kancera AB
  • LondonPharma Ltd
  • MORE

Schistosomiasis - Pipeline Review, H1 2015

Summary

This, ‘Schistosomiasis - Pipeline Review, H1 2015’, provides an overview of the Schistosomiasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioDiem Ltd
  • Kancera AB
  • LondonPharma Ltd
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Schistosomiasis Overview
Therapeutics Development
Pipeline Products for Schistosomiasis - Overview
Pipeline Products for Schistosomiasis - Comparative Analysis
Schistosomiasis - Therapeutics under Development by Companies
Schistosomiasis - Therapeutics under Investigation by Universities/Institutes
Schistosomiasis - Pipeline Products Glance
Early Stage Products
Schistosomiasis - Products under Development by Companies
Schistosomiasis - Products under Investigation by Universities/Institutes
Schistosomiasis - Companies Involved in Therapeutics Development
BioDiem Ltd
Concert Pharmaceuticals, Inc.
Kancera AB
LondonPharma Ltd
Schistosomiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BDM-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-Praziquantel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
intestinal schistosomiasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Schistosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Schistosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Schistosomiasis - Recent Pipeline Updates
Schistosomiasis - Dormant Projects
Schistosomiasis - Product Development Milestones
Featured News & Press Releases
Aug 23, 2013: BioDiem US patent for skin and wound infections
Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Schistosomiasis, H1 2015
Number of Products under Development for Schistosomiasis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Schistosomiasis - Pipeline by BioDiem Ltd, H1 2015
Schistosomiasis - Pipeline by Concert Pharmaceuticals, Inc., H1 2015
Schistosomiasis - Pipeline by Kancera AB, H1 2015
Schistosomiasis - Pipeline by LondonPharma Ltd, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
umber of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Schistosomiasis Therapeutics - Recent Pipeline Updates, H1 2015
Schistosomiasis - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Schistosomiasis, H1 2015
Number of Products under Development for Schistosomiasis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

BioDiem Ltd
Concert Pharmaceuticals, Inc.
Kancera AB
LondonPharma Ltd

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.